|Bid||17.72 x 200|
|Ask||17.75 x 100|
|Day's Range||17.30 - 18.06|
|52 Week Range||3.82 - 26.05|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 3, 2017 - Aug 7, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.50|
GlycoMimetics, Inc. , a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced the pricing of its underwritten public offering of 7,000,000 shares of its common stock at a price to the public of $17.00 per share.
GlycoMimetics, Inc. , a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced that it intends to offer and sell, subject to market conditions, 4,500,000 shares of its common stock in an underwritten public offering.
GlycoMimetics, Inc. announced today that preclinical research suggesting the potential of two of its drug candidates, GMI-1271 and GMI-1359, as treatments for acute myeloid leukemia , metastasis in osteosarcoma and other cancers will be shared via poster presentations at the American Association for Cancer Research Annual Meeting 2018 in Chicago.
GlycoMimetics, Inc. announced today that it will present at four investor conferences during the month of March, including:
NEW YORK, NY / ACCESSWIRE / March 6, 2018 / U.S. markets rallied Monday, with the Dow breaking a streak of 4 consecutive losses, as concerns over a potential trade war eased. The Dow Jones Industrial Average ...
The Rockville, Maryland-based company said it had a loss of 27 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
GlycoMimetics, Inc. today reported progress on its clinical development programs and its financial results for the fourth quarter and year ended December 31, 2017.
NEW YORK, NY / ACCESSWIRE / March 6, 2018 / GlycoMimetics, Inc. (NASDAQ: GLYC ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 6, 2018 at 8:30 AM Eastern Time. ...
GlycoMimetics, Inc. announced today its design for a randomized, double-blind, placebo-controlled Phase 3 clinical trial to evaluate GMI-1271 in combination with MEC or in combination with FAI in individuals with relapsed/refractory acute myeloid leukemia .
GlycoMimetics Inc’s (NASDAQ:GLYC): GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the UnitedRead More...
GlycoMimetics (GLYC) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
GlycoMimetics, Inc. announced today that it will host a conference call and webcast to provide an update on development plans for GMI-1271 in acute myeloid leukemia as well as to report its fourth quarter and fiscal year 2017 financial results on Tuesday, March 6, 2018, at 8:30 a.m.
GlycoMimetics, Inc. announced today that it has entered into an agreement with the Haemato Oncology Foundation for Adults in the Netherlands group to initiate clinical trial startup activities.
NEW YORK, Jan. 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of NanoString ...
Zero-debt allows substantial financial flexibility, especially for small-cap companies like GlycoMimetics Inc (NASDAQ:GLYC), as the company does not have to adhere to strict debt covenants. However, it also faces higherRead More...
There's talk that tax reform could give biotech M&A a kick-start. If it does, then investors will want to keep tabs on these stocks.
Assessing GlycoMimetics Inc’s (NASDAQ:GLYC) performance as a company requires looking at more than just a years’ earnings data. Below, I will run you through a simple sense check to buildRead More...
A wholly owned cancer drug could eventually reshape an important indication, and a new sickle-cell disease drug could be heading to the FDA as soon as next year.
GlycoMimetics, Inc. today announced that it will be included in the NASDAQ Biotechnology Index® . The annual re-ranking of the NASDAQ Biotechnology Index will be effective prior to market upon on Monday, December 18, 2017.